Literature DB >> 22768831

Leptin in the liver: a toxic or beneficial mix?

Marc L Reitman.   

Abstract

Although obesity is associated with nonalcoholic fatty liver disease (NAFLD), the causal mechanisms are unclear. In this issue, Imajo et al. (2012) show that, in mice, leptin enhances the effects of bacterial endotoxin, promoting the development of NAFLD.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Year:  2012        PMID： 22768831      PMCID： PMC3394672          DOI： 10.1016/j.cmet.2012.06.009

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


  9 in total

1.  The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

Review 2.  Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.

Authors:  G Vernon; A Baranova; Z M Younossi
Journal:  Aliment Pharmacol Ther       Date:  2011-05-30       Impact factor: 8.171

Review 3.  Human fatty liver disease: old questions and new insights.

Authors:  Jonathan C Cohen; Jay D Horton; Helen H Hobbs
Journal:  Science       Date:  2011-06-24       Impact factor: 47.728

4.  Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.

Authors:  Edward D Javor; Marc G Ghany; Elaine K Cochran; Elif Arioglu Oral; Alex M DePaoli; Ahalya Premkumar; David E Kleiner; Phillip Gorden
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425

Review 5.  Animal models of nonalcoholic fatty liver disease.

Authors:  Lionel Hebbard; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-30       Impact factor: 46.802

6.  Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase.

Authors:  Manju Kumari; Gabriele Schoiswohl; Chandramohan Chitraju; Margret Paar; Irina Cornaciu; Ashraf Y Rangrez; Nuttaporn Wongsiriroj; Harald M Nagy; Pavlina T Ivanova; Sarah A Scott; Oskar Knittelfelder; Gerald N Rechberger; Ruth Birner-Gruenberger; Sandra Eder; H Alex Brown; Guenter Haemmerle; Monika Oberer; Achim Lass; Erin E Kershaw; Robert Zimmermann; Rudolf Zechner
Journal:  Cell Metab       Date:  2012-05-02       Impact factor: 27.287

7.  Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.

Authors:  Elizabeth K Speliotes; Laura M Yerges-Armstrong; Jun Wu; Ruben Hernaez; Lauren J Kim; Cameron D Palmer; Vilmundur Gudnason; Gudny Eiriksdottir; Melissa E Garcia; Lenore J Launer; Michael A Nalls; Jeanne M Clark; Braxton D Mitchell; Alan R Shuldiner; Johannah L Butler; Marta Tomas; Udo Hoffmann; Shih-Jen Hwang; Joseph M Massaro; Christopher J O'Donnell; Dushyant V Sahani; Veikko Salomaa; Eric E Schadt; Stephen M Schwartz; David S Siscovick; Benjamin F Voight; J Jeffrey Carr; Mary F Feitosa; Tamara B Harris; Caroline S Fox; Albert V Smith; W H Linda Kao; Joel N Hirschhorn; Ingrid B Borecki
Journal:  PLoS Genet       Date:  2011-03-10       Impact factor: 5.917

8.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.

Authors:  Stefano Romeo; Julia Kozlitina; Chao Xing; Alexander Pertsemlidis; David Cox; Len A Pennacchio; Eric Boerwinkle; Jonathan C Cohen; Helen H Hobbs
Journal:  Nat Genet       Date:  2008-09-25       Impact factor: 38.330

9.  Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency.

Authors:  I Sadaf Farooqi; Giuseppe Matarese; Graham M Lord; Julia M Keogh; Elizabeth Lawrence; Chizo Agwu; Veronica Sanna; Susan A Jebb; Francesco Perna; Silvia Fontana; Robert I Lechler; Alex M DePaoli; Stephen O'Rahilly
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808
  9 in total
  5 in total

1.  The liver diseases of lipodystrophy: the long-term effect of leptin treatment.

Authors:  Elika Safar Zadeh; Andreea O Lungu; Elaine K Cochran; Rebecca J Brown; Marc G Ghany; Theo Heller; David E Kleiner; Phillip Gorden
Journal:  J Hepatol       Date:  2013-02-21       Impact factor: 25.083

Review 2.  Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.

Authors:  Cristina Adelia Meehan; Elaine Cochran; Andrea Kassai; Rebecca J Brown; Phillip Gorden
Journal:  Expert Rev Clin Pharmacol       Date:  2015-10-14       Impact factor: 5.045

3.  Effects of metreleptin on proteinuria in patients with lipodystrophy.

Authors:  Ho Lim Lee; Meryl A Waldman; Sungyoung Auh; James E Balow; Elaine K Cochran; Phillip Gorden; Rebecca J Brown
Journal:  J Clin Endocrinol Metab       Date:  2019-04-16       Impact factor: 5.958

Review 4.  Unraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases.

Authors:  Maite Martínez-Uña; Yaiza López-Mancheño; Carlos Diéguez; Manuel A Fernández-Rojo; Marta G Novelle
Journal:  Int J Mol Sci       Date:  2020-12-09       Impact factor: 5.923

Review 5.  Non-Alcoholic Fatty Liver Disease in HIV/HBV Patients - a Metabolic Imbalance Aggravated by Antiretroviral Therapy and Perpetuated by the Hepatokine/Adipokine Axis Breakdown.

Authors:  Simona Alexandra Iacob; Diana Gabriela Iacob
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-09       Impact factor: 5.555
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.